title: [Efficacy of donor lymphocyte infusion in patients after different types of allogeneic hematopoietic stem cell transplantation].
abstract: OBJECTIVE
  To evaluate the efficacy of donor lymphocyte infusion (DLI) to prevent and treat recurrences in patients after different types of allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  
  
  METHODS
  Data from 118 patients with malignant blood diseases were analyzed. Allo-HSCTs from HLA-matched related donors (n=49), HLA-matched unrelated donors (n=50), partially HLA-matched unrelated donors (n=2), and haploidentical donors (n=24) were performed. The indications for DLI were underlying disease relapse (59 DLIs), resistant disease course (n=40), minimal residual disease (n=1 6), falling donor chimerism (n=1 5), and recurrence prevention (n=1 3).
  
  
  RESULTS
  Therapy response was obtained after 57 (44%) DLls. There were 36 (25%) and 30 (21%) cases of acute and chronic graft-versus-host reactions (GVHR), respectively. The use of DLI from HLA-matched donors, its performance in the periods of D+100 to one year after allo-HSCT, a donor chimerism level of over 90% at the moment of DLI, the administration of the initial DLI dose of below 1.10(6) CD3+/kg, and the development of chronic GVHR after DLI were associated with the highest rate of therapy responses. The overall survival rates of patients with DLI were significantly influenced by factors, such as DLI periods, donor chimerism levels at DLI, and the development of chronic CVHR after DLI.
  
  
  CONCLUSIONS
  The choice of the optimal dose of cells, the periods of DLI and its preventive administration improve prognosis in patients after allo-HSCT. The occurrence of acute GVHR is affected by the degree of HLA matching and the type of a donor. The development of chronic GVHR after DLI is associated with the highest rate of responses to DLI and higher survival rates.
authors.forename: O A
authors.initials: OA
authors.lastname: Slesarchuk
authors.forename: E V
authors.initials: EV
authors.lastname: Babenko
authors.forename: E V
authors.initials: EV
authors.lastname: Semenova
authors.forename: S N
authors.initials: SN
authors.lastname: Bondarenko
authors.forename: M A
authors.initials: MA
authors.lastname: Éstrina
authors.forename: E V
authors.initials: EV
authors.lastname: Morozova
authors.forename: O V
authors.initials: OV
authors.lastname: Paina
authors.forename: V N
authors.initials: VN
authors.lastname: Vavilov
authors.forename: B I
authors.initials: BI
authors.lastname: Smirnov
authors.forename: L S
authors.initials: LS
authors.lastname: Zubarovskaia
authors.forename: B V
authors.initials: BV
authors.lastname: Afanas'ev
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001782:Blood Donors; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006648:Histocompatibility; D006801:Humans; D007223:Infant; D053208:Kaplan-Meier Estimate; D007938:Leukemia / Q000628:therapy; D017710:Lymphocyte Transfusion / Q000379:methods*; D008223:Lymphoma / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000628:therapy; D055502:Secondary Prevention; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D061349:Unrelated Donors; D055815:Young Adult